Avenue Therapeutics, Inc. (ATXI) Income Statement
ATXI 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsATXI revenue and net income
Where ATXI's revenue goes
2025Each bar shows an amount and its share of revenue. ATXI kept −207.2% of revenue as net income.
ATXI profit margins
ATXI growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ATXI quarterly EPS vs estimates
Avenue Therapeutics beat the analyst EPS estimate in 3 of the last 7 quarters.
ATXI income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | — | — | — | — | — | — | $0 | $0 | $0 |
| Gross profit | $1.4M | — | — | — | — | — | — | $0 | $0 | $0 |
| Research & development | $1.0M | $6.6M | $10.4M | $2.7M | $1.3M | $2.9M | $23.2M | $17.7M | $7.8M | $1.4M |
| Sales, general & admin | $3.7M | $4.6M | $4.2M | $5.3M | $2.5M | $2.3M | $3.1M | $4.1M | $3.6M | $997,000 |
| Total operating expenses | $4.7M | $11.3M | $14.5M | $8.0M | $3.7M | $5.2M | $26.3M | $21.8M | $6.7M | $2.4M |
| Operating income | −$3.3M | −$11.3M | −$14.5M | −$8.0M | −$3.7M | −$5.2M | −$26.3M | −$21.8M | −$11.4M | −$2.4M |
| Interest income | $121,000 | $176,000 | $126,000 | $20,000 | $7,000 | $62,000 | $357,000 | $93,000 | $88,000 | $730,000 |
| Interest expense | — | $0 | $332,000 | $1.2M | $7,000 | $0 | $0 | $0 | $375,000 | $612,000 |
| Income before taxes | −$2.9M | −$11.7M | −$10.5M | −$3.6M | −$3.7M | −$5.2M | −$25.9M | −$21.5M | −$12.3M | −$3.2M |
| Income taxes | — | — | −$111,000 | −$5.7M | −$7,000 | −$62,000 | −$357,000 | −$268,000 | $287,000 | −$1.8M |
| Net income | −$2.9M | −$11.7M | −$10.4M | −$3.6M | −$3.7M | −$5.1M | −$25.6M | −$21.5M | −$12.3M | −$3.2M |
| EBITDA | −$3.3M | −$11.7M | $4.1M | −$2.4M | −$3.7M | −$5.2M | −$26.3M | $268,000 | −$11.7M | −$2.4M |
| EPS (diluted) | −$0.93 | −$15.90 | −$35.79 | −$132.76 | −$191.30 | −$282.15 | −$1568.70 | −$1951.80 | −$1.70 | −$5.39 |
| Gross margin | 100.0% | — | — | — | — | — | — | — | — | — |
| Operating margin | −234.0% | — | — | — | — | — | — | — | — | — |
| Net margin | −207.2% | — | — | — | — | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.4M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | $1.4M | — | $0 | — | — | — | — | — | — | — |
| Gross profit | — | — | −$1.4M | — | $1.4M | — | — | — | — | — | — | — |
| Research & development | $247,000 | $200,000 | $257,000 | $177,000 | $192,000 | $411,000 | $565,000 | $2.3M | $1.4M | $2.4M | $982,000 | $907,000 |
| Sales, general & admin | $460,000 | $514,000 | $697,000 | $547,000 | $915,000 | $1.5M | $1.0M | $829,000 | $1.5M | $1.3M | $1.1M | $1.2M |
| Total operating expenses | $707,000 | $714,000 | $752,000 | $724,000 | $1.1M | $1.9M | $1.6M | $3.2M | $2.8M | $3.7M | $2.1M | $2.1M |
| Operating income | −$707,000 | −$714,000 | −$752,000 | −$724,000 | $297,000 | −$1.9M | −$1.6M | −$3.2M | −$2.8M | −$3.7M | −$2.1M | −$2.1M |
| Interest income | $17,000 | $18,000 | $25,000 | $34,000 | $31,000 | $32,000 | $24,000 | $51,000 | $52,000 | $49,000 | $22,000 | $9,000 |
| Interest expense | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $332,000 | $0 |
| Income before taxes | −$690,000 | −$695,000 | −$726,000 | −$683,000 | $329,000 | −$1.9M | −$1.6M | −$3.1M | −$2.7M | −$4.3M | $617,000 | $513,000 |
| Income taxes | — | — | — | — | — | — | −$9,000 | — | $4.5M | $9,000 | −$23,000 | −$2,068 |
| Net income | −$690,000 | −$695,000 | −$709,000 | −$683,000 | $335,000 | −$1.9M | −$1.5M | −$3.1M | −$7.2M | −$4.3M | $640,000 | $526,000 |
| EBITDA | −$707,000 | −$714,000 | −$955,000 | −$683,000 | $297,000 | −$1.9M | −$1.6M | $69,000 | $123,000 | −$3.7M | $2.7M | $513,000 |
| EPS (diluted) | — | — | — | −$0.21 | $0.11 | −$0.73 | $3.83 | −$1.92 | −$2.41 | −$15.40 | $0.06 | $4.50 |
| Gross margin | — | — | — | — | 100.0% | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | 21.2% | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | 23.9% | — | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ATXI's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ATXI financial results
In fiscal year 2025 (ended December 31, 2025), Avenue Therapeutics reported revenue of $1.4 million. It had a net loss of $2.9 million, a net profit margin of −207.2%. Diluted earnings per share came to −$0.93.
See the ATXI stock overview for the latest quote and news, or the ATXI chart for price history and technical indicators.
ATXI income statement FAQ
What is Avenue Therapeutics's annual revenue?
Avenue Therapeutics reported total revenue of $1.4 million for fiscal year 2025, which ended on December 31, 2025.
Is Avenue Therapeutics profitable?
No. Avenue Therapeutics reported a net loss of $2.9 million in fiscal 2025, a net profit margin of −207.2%; its operating margin was −234.0%.
What is Avenue Therapeutics's gross margin?
Avenue Therapeutics's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Avenue Therapeutics kept $100 after the direct cost of its products and services.
How much does Avenue Therapeutics spend on research and development?
Avenue Therapeutics spent $1.0 million on research and development in fiscal 2025, 73.9% of revenue.
What are Avenue Therapeutics's earnings per share?
Avenue Therapeutics earned $-0.93 per diluted share in fiscal 2025, compared with $-15.90 a year earlier.
When does Avenue Therapeutics's fiscal year end?
Avenue Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.